These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21509737)

  • 1. [New drugs in chronic obstructive pulmonary disease].
    Chazan RC
    Pneumonol Alergol Pol; 2011; 79(3):232-8. PubMed ID: 21509737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
    Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H
    Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary medicine. Two new drugs for the treatment of COPD].
    Rochat T
    Rev Med Suisse; 2011 Jan; 7(278):145-6, 148-9. PubMed ID: 21400948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
    Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
    Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
    Pelaia G; Maselli R; Matera MG
    Pharmacology; 2014; 94(5-6):249-58. PubMed ID: 25471458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ; Giembycz MA; Rennard SI
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
    Tashkin DP
    Expert Opin Pharmacother; 2010 Aug; 11(12):2077-85. PubMed ID: 20642373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM; Beier J
    Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
    Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM
    Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators.
    Hanania NA; Donohue JF
    Proc Am Thorac Soc; 2007 Oct; 4(7):526-34. PubMed ID: 17878465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC; Lau H; La HO; Choi IS; Geba GP
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
    Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
    Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical profile of roflumilast].
    Izquierdo Alonso JL
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
    Tashkin DP
    Expert Opin Pharmacother; 2014 Jan; 15(1):85-96. PubMed ID: 24032576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.